Switch to:
Also traded in: Germany, Israel, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.36
OPK's Cash to Debt is ranked lower than
76% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. OPK: 1.36 )
Ranked among companies with meaningful Cash to Debt only.
OPK' s Cash to Debt Range Over the Past 10 Years
Min: 0.48  Med: 20.90 Max: No Debt
Current: 1.36
Equity to Asset 0.71
OPK's Equity to Asset is ranked higher than
53% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. OPK: 0.71 )
Ranked among companies with meaningful Equity to Asset only.
OPK' s Equity to Asset Range Over the Past 10 Years
Min: 0.02  Med: 0.63 Max: 0.96
Current: 0.71
0.02
0.96
F-Score: 7
Z-Score: 4.05
M-Score: 2.04
WACC vs ROIC
14.76%
-9.28%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -20.03
OPK's Operating margin (%) is ranked higher than
60% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. OPK: -20.03 )
Ranked among companies with meaningful Operating margin (%) only.
OPK' s Operating margin (%) Range Over the Past 10 Years
Min: -31624.44  Med: -82.88 Max: -20.03
Current: -20.03
-31624.44
-20.03
Net-margin (%) -6.11
OPK's Net-margin (%) is ranked higher than
65% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. OPK: -6.11 )
Ranked among companies with meaningful Net-margin (%) only.
OPK' s Net-margin (%) Range Over the Past 10 Years
Min: -31688.9  Med: -118.52 Max: -4.59
Current: -6.11
-31688.9
-4.59
ROE (%) -2.33
OPK's ROE (%) is ranked higher than
72% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. OPK: -2.33 )
Ranked among companies with meaningful ROE (%) only.
OPK' s ROE (%) Range Over the Past 10 Years
Min: -3196.93  Med: -21.01 Max: -2.13
Current: -2.33
-3196.93
-2.13
ROA (%) -1.48
OPK's ROA (%) is ranked higher than
74% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. OPK: -1.48 )
Ranked among companies with meaningful ROA (%) only.
OPK' s ROA (%) Range Over the Past 10 Years
Min: -1352.71  Med: -13.92 Max: -0.83
Current: -1.48
-1352.71
-0.83
ROC (Joel Greenblatt) (%) -174.84
OPK's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. OPK: -174.84 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OPK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -130662.93  Med: -367.75 Max: -55.31
Current: -174.84
-130662.93
-55.31
Revenue Growth (3Y)(%) 85.10
OPK's Revenue Growth (3Y)(%) is ranked higher than
92% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. OPK: 85.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OPK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -11.60 Max: 152
Current: 85.1
0
152
EBITDA Growth (3Y)(%) 27.70
OPK's EBITDA Growth (3Y)(%) is ranked higher than
80% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. OPK: 27.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OPK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -74.6  Med: 6.60 Max: 161.2
Current: 27.7
-74.6
161.2
EPS Growth (3Y)(%) -16.40
OPK's EPS Growth (3Y)(%) is ranked lower than
65% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. OPK: -16.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OPK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -69.4  Med: -1.60 Max: 149.7
Current: -16.4
-69.4
149.7
» OPK's 10-Y Financials

Financials (Next Earnings Date: 2016-05-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

OPK Guru Trades in Q2 2015

Joel Greenblatt 42,947 sh (New)
Paul Tudor Jones 119,791 sh (+214.11%)
Jim Simons 1,907,498 sh (+52.19%)
Murray Stahl 96,810 sh (+2.09%)
George Soros 235,600 sh (unchged)
Ken Fisher 29,200 sh (unchged)
Mario Gabelli 10,000 sh (-9.09%)
» More
Q3 2015

OPK Guru Trades in Q3 2015

John Hussman 750,000 sh (New)
Chuck Royce 521,525 sh (New)
Mario Gabelli 169,900 sh (+1599.00%)
Ken Fisher 35,500 sh (+21.58%)
Jim Simons Sold Out
Joel Greenblatt Sold Out
George Soros Sold Out
Murray Stahl 94,118 sh (-2.78%)
Paul Tudor Jones 46,800 sh (-60.93%)
» More
Q4 2015

OPK Guru Trades in Q4 2015

George Soros 55,500 sh (New)
Joel Greenblatt 120,369 sh (New)
Ken Fisher 37,826 sh (+6.55%)
John Hussman Sold Out
Chuck Royce Sold Out
Mario Gabelli 144,775 sh (-14.79%)
Murray Stahl 79,624 sh (-15.40%)
Paul Tudor Jones 26,500 sh (-43.38%)
» More
Q1 2016

OPK Guru Trades in Q1 2016

Ken Fisher 37,867 sh (+0.11%)
Murray Stahl 67,206 sh (-15.60%)
» More
» Details

Insider Trades

Latest Guru Trades with OPK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Opko Health Inc

Weekly CEO Buys Highlights Citigroup, Opko, JMP Group, Tuesday Morning, Calamos lead list, according to GuruFocus Insider Data
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: FS Investment, Opko, Ambac, Calamos, Praxair These are the largest CEO buys during the past week, according to GuruFocus' Insider Data
These are the largest CEO buys during the past week, according to GuruFocus' Insider Data. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: GHL, OPK, DKL, ATI, PEB A look at recent insider buys from CEOs
According to GuruFocus Insider Data, these were the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: Box, Opko, Neonode, FS Investment, Celator Pharmaceuticals GuruFocus Insider Data identifies CEOs' largest buys in the past week.
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: CC, OPK, PX, PSG, JOY A roundup of recent insider buys
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEO buys is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: Tesla, Opko, MasTec, NSA Trust, Conifer Holdings
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
Forward P/E 29.07
OPK's Forward P/E is ranked lower than
81% of the 85 Companies
in the Global Biotechnology industry.

( Industry Median: 17.79 vs. OPK: 29.07 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 23.72
OPK's Price/Owner Earnings (ttm) is ranked higher than
62% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 36.86 vs. OPK: 23.72 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
OPK' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 18.1  Med: 92.59 Max: 4990
Current: 23.72
18.1
4990
P/B 2.84
OPK's P/B is ranked higher than
56% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. OPK: 2.84 )
Ranked among companies with meaningful P/B only.
OPK' s P/B Range Over the Past 10 Years
Min: 2.17  Med: 8.91 Max: 800
Current: 2.84
2.17
800
P/S 10.31
OPK's P/S is ranked higher than
51% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. OPK: 10.31 )
Ranked among companies with meaningful P/S only.
OPK' s P/S Range Over the Past 10 Years
Min: 7.87  Med: 34.29 Max: 158.13
Current: 10.31
7.87
158.13
PFCF 29.65
OPK's PFCF is ranked higher than
50% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 30.80 vs. OPK: 29.65 )
Ranked among companies with meaningful PFCF only.
OPK' s PFCF Range Over the Past 10 Years
Min: 22.61  Med: 32.75 Max: 49.07
Current: 29.65
22.61
49.07
POCF 27.14
OPK's POCF is ranked lower than
55% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. OPK: 27.14 )
Ranked among companies with meaningful POCF only.
OPK' s POCF Range Over the Past 10 Years
Min: 20.71  Med: 30.73 Max: 47.82
Current: 27.14
20.71
47.82
Current Ratio 1.80
OPK's Current Ratio is ranked lower than
79% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. OPK: 1.80 )
Ranked among companies with meaningful Current Ratio only.
OPK' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 4.09 Max: 42.13
Current: 1.8
1.22
42.13
Quick Ratio 1.64
OPK's Quick Ratio is ranked lower than
76% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. OPK: 1.64 )
Ranked among companies with meaningful Quick Ratio only.
OPK' s Quick Ratio Range Over the Past 10 Years
Min: 1.08  Med: 3.68 Max: 42.13
Current: 1.64
1.08
42.13
Days Inventory 42.15
OPK's Days Inventory is ranked higher than
81% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. OPK: 42.15 )
Ranked among companies with meaningful Days Inventory only.
OPK' s Days Inventory Range Over the Past 10 Years
Min: 43.67  Med: 233.05 Max: 500.07
Current: 42.15
43.67
500.07
Days Sales Outstanding 143.91
OPK's Days Sales Outstanding is ranked lower than
81% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. OPK: 143.91 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.86  Med: 163.64 Max: 727.85
Current: 143.91
38.86
727.85
Days Payable 112.55
OPK's Days Payable is ranked higher than
68% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. OPK: 112.55 )
Ranked among companies with meaningful Days Payable only.
OPK' s Days Payable Range Over the Past 10 Years
Min: 66.48  Med: 112.55 Max: 1499.3
Current: 112.55
66.48
1499.3

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 3.60
OPK's Price/Projected FCF is ranked lower than
51% of the 176 Companies
in the Global Biotechnology industry.

( Industry Median: 3.66 vs. OPK: 3.60 )
Ranked among companies with meaningful Price/Projected FCF only.
OPK' s Price/Projected FCF Range Over the Past 10 Years
Min: 3.5  Med: 11.72 Max: 62.44
Current: 3.6
3.5
62.44
Price/Median PS Value 0.30
OPK's Price/Median PS Value is ranked higher than
89% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. OPK: 0.30 )
Ranked among companies with meaningful Price/Median PS Value only.
OPK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.29  Med: 1.23 Max: 30
Current: 0.3
0.29
30
Price/Graham Number 11.75
OPK's Price/Graham Number is ranked lower than
97% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. OPK: 11.75 )
Ranked among companies with meaningful Price/Graham Number only.
OPK' s Price/Graham Number Range Over the Past 10 Years
Min: 3.86  Med: 4.38 Max: 14.36
Current: 11.75
3.86
14.36
Earnings Yield (Greenblatt) (%) -2.29
OPK's Earnings Yield (Greenblatt) (%) is ranked higher than
65% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. OPK: -2.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OPK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -7.03  Med: 0.00 Max: 0
Current: -2.29
-7.03
0

More Statistics

Revenue(Mil) $492
EPS $ -0.10
Beta1.76
Short Percentage of Float21.20%
52-Week Range $7.12 - 19.20
Shares Outstanding(Mil)545.84

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 1,092 1,461 2,057
EPS($) -0.01 0.36 0.81
EPS without NRI($) -0.01 0.36 0.81

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, OCSE:NOVO B, NAS:GILD, NAS:AMGN, NAS:CELG, NAS:BIIB » details
Traded in other countries:XCY.Germany, OPK.Israel, OPK.Mexico,
Opko Health Inc was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics, Inc. The Company is a multi-national biopharmaceutical and diagnostics company. It is developing various solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests, molecular diagnostics tests, and proprietary pharmaceuticals and vaccines. It owns established pharmaceutical platforms in Chile, Spain, Mexico and Uruguay. It also has established pharmaceutical operations in Brazil. The Company owns a specialty active pharmaceutical ingredients manufacturer in Israel. The Company currently manages its operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of two operating segments, its (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products and vaccines, and (ii) the pharmaceutical operations it acquired in Chile, Spain, Mexico, Israel, Spain, Uruguay and Brazil. The diagnostics segment consists of two operating segments, the Companys (i) pathology operations it acquired through the acquisition of OPKO Lab and (ii) point-of-care and molecular diagnostics operations. Its main products Rayaldy and Alpharen are in phase 3 clinical development. Its competitors include diagnostic companies, reference laboratories, molecular diagnostic firms, universities and research institutions. The testing, manufacture, distribution, advertising, and marketing of drug and diagnostic products and medical devices are subject to extensive regulation by federal, state, and local governmental authorities in the U.S., including the FDA, and by similar agencies in other countries.
» More Articles for OPK

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlights Mar 14 2016 
Weekly CEO Buys Highlights Jan 26 2016 
Weekly CEO Buys Highlight: FS Investment, Opko, Ambac, Calamos, Praxair Jan 11 2016 
Weekly CEO Buys Highlights for the Final Week of 2015 Jan 04 2016 
Weekly CEO Buys Highlight: Prospect Capital, Sears Holdings, Calamos Asset Management, Opko Health, Dec 28 2015 
Weekly CEO Buys Highlight: GHL, OPK, DKL, ATI, PEB Nov 02 2015 
Weekly CEO Buys Highlight: Box, Opko, Neonode, FS Investment, Celator Pharmaceuticals Oct 16 2015 
Weekly CEO Buys Highlight: CC, OPK, PX, PSG, JOY Sep 12 2015 
Weekly CEO Buys Highlight: Shutterstock, Endurance Specialty Holdings, Opko, Air Products, KapStone Aug 31 2015 
Top Insider Buys of the Week Aug 28 2015 

More From Other Websites
OPKO to Announce First Quarter Operating and Financial Results on May 9, 2016 Apr 28 2016
OPKO to Announce First Quarter Operating and Financial Results on May 9, 2016 Apr 28 2016
OPKO Offers Additional Data On RAYALDEE At National Kidney Foundation Spring Clinical Meetings Apr 28 2016
OPKO Presents Additional Data on RAYALDEE® at National Kidney Foundation Spring Clinical Meetings... Apr 28 2016
Insiders Are Scooping Up These 5 Stocks Apr 27 2016
OPKO Health Says FDA Accepts Resubmission Of NDA For Its RAYALDEE Apr 27 2016
FDA Accepts Resubmission of New Drug Application for RAYALDEE® Apr 27 2016
FDA Accepts Resubmission of New Drug Application for RAYALDEE® Apr 27 2016
OPKO Health Appoints James DeMarco As SVP Of Pharmaceutical Sales Apr 25 2016
OPKO Announces Appointment of James DeMarco as Senior Vice President of Pharmaceutical Sales Apr 25 2016
OPKO Announces Appointment of James DeMarco as Senior Vice President of Pharmaceutical Sales Apr 25 2016
Cocrystal Pharma Receives Health Canada Approval to Conduct Phase I Clinical Study for CC-31244 in... Apr 25 2016
Cocrystal Pharma Receives Health Canada Approval to Conduct Phase I Clinical Study for CC-31244 in... Apr 25 2016
5 Toxic Stocks to Get Rid Of Now Apr 22 2016
Weekly Biotech Report Covering Opko Health Inc (NYSE:OPK) Intercept Pharmaceuticals (NASDAQ:ICPT)... Apr 11 2016
This Company Just Inked A Deal Contingent On Generating Earnings Per Share Apr 08 2016
5 Stocks Insiders Love Right Now Apr 06 2016
OPKO HEALTH, INC. Files SEC form 8-K, Other Events Apr 06 2016
Top 6 Biopharma Movers of the Past Week Apr 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK